September 06, 2017
Pharmaceutical company Impax Laboratories Inc. will pay $4.8 million to end a proposed class action alleging it sent "blasts" of unsolicited faxes advertising a low-cost alternative to Mylan's EpiPen, according to a Tuesday filing in Alabama federal court.